Gilsenan A, Shakir S, Jokinen J. Pharmacovigilance: beyond signal detection and spontaneous reporting. Presentation to be given at the DIA 2025 Global Annual Meeting; June 16, 2025. Washington, DC.
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Harris DH, Gilsenan AW, Wu Y, Andrews EB. Using cancer surveillance data to advance science: monitoring for a potential safety signal for approved drugs through linkage studies. Poster presented at the Annual Meeting of the North American Association of Central Cancer Registries; 2012.